Several studies have characterized the association of TP53 mutations with clinical outcomes in breast cancer [4], non-small-cell lung cancer [5], cholangiocarcinoma [6], thymic carcinoma [7], and in pan-cancers [8, 9]. This evidence concerns the gene TP53 and cancer.